Brivanib Attenuates Hepatic Fibrosis In Vivo and Stellate Cell Activation In Vitro by Inhibition of FGF, VEGF and PDGF Signaling

BACKGROUND AND AIMS: Brivanib is a selective inhibitor of vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) tyrosine kinases, which are both involved in mechanisms of liver fibrosis. We hypothesized that inhibition of VEGFR and FGFR by brivanib would in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Ikuo, Zakharia, Kais, Banini, Bubu A., Mikhail, Dalia S., Kim, Tae Hyo, Yang, Ju Dong, Moser, Catherine D., Shaleh, Hassan M., Thornburgh, Sarah R., Walters, Ian, Roberts, Lewis R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977817/
https://www.ncbi.nlm.nih.gov/pubmed/24710173
http://dx.doi.org/10.1371/journal.pone.0092273

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977817/
https://www.ncbi.nlm.nih.gov/pubmed/24710173
http://dx.doi.org/10.1371/journal.pone.0092273

Ejemplares similares